QL1706

Overview

QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

Background

QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer	2025/06/17	NCT07025239	Phase 3	Not yet recruiting	Qilu Pharmaceutical Co., Ltd.
QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC	2025/06/06	NCT07009145	Phase 2	Not yet recruiting	Qianfoshan Hospital
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma	2025/06/03	NCT07002346	Phase 3	Not yet recruiting	Tongji Hospital
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer	2025/05/13	NCT06967103	Phase 2	Not yet recruiting	Henan Cancer Hospital
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer	2025/04/30	NCT06951997	Phase 2	Not yet recruiting	Tianjin Medical University Cancer Institute and Hospital
Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors	2025/04/24	NCT06941766	Phase 1	Recruiting	Peking Union Medical College Hospital
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma	2025/04/23	NCT06939855	Phase 2	Recruiting	Sun Yat-sen University
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC	2025/03/26	NCT06897046	Phase 2	Not yet recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
QL1706 Combined with Lenvatinib and GEMOX As First - Line Treatment for Unresectable Biliary Tract Tumors	2025/03/25	NCT06892925	Phase 2	Not yet recruiting	Eastern Hepatobiliary Surgery Hospital
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma	2025/03/25	NCT06893887	Not Applicable	Recruiting	Nanjing Tianyinshan Hospital

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access